Zinc-dependent Zip7-MAZ-MYBL2 axis promotes prostate cancer metastasis

Area of Science:

• Oncology
• Molecular Biology
• Trace Element Research

Background:

• Zinc is crucial for prostate health and its levels decrease during prostate cancer development.
• The precise mechanisms linking zinc signaling to prostate cancer (PCa) progression, particularly metastasis, remain unclear.
• Identifying key molecular players in zinc dysregulation is vital for developing novel PCa therapies.

Purpose of the Study:

• To investigate the role of zinc transporter Zip7 in prostate cancer metastasis.
• To elucidate the molecular mechanisms by which Zip7 influences PCa progression.
• To evaluate Zip7 as a therapeutic target for advanced prostate cancer.

Main Methods:

• Analysis of zinc levels and Zip7 expression in PCa tissues, including metastatic samples.
• In vitro studies involving Zip7 silencing to assess effects on PCa cell migration and invasion.
• In vivo experiments using xenograft models to evaluate the impact of Zip7 on bone metastasis.
• Mechanistic studies involving protein-protein interactions (Zip7-MAZ), nuclear import, and gene expression analysis (RNA-seq).
• Pharmacological inhibition of Zip7 in a bone metastasis model.

Main Results:

• Zinc levels are significantly reduced in PCa, especially in metastatic cases.
• Zip7 is upregulated in metastatic PCa and correlates with poor prognosis.
• Zip7 silencing inhibits PCa cell migration, invasion, and bone metastasis in vivo.
• Zip7 facilitates the nuclear import of MAZ, which is upregulated in metastatic PCa and promotes metastasis.
• Zip7-mediated MAZ nuclear import upregulates MYBL2 transcription, driving PCa metastasis.
• Inhibition of Zip7 significantly suppressed PCa bone metastasis in a xenograft model.

Conclusions:

• Zip7 is a critical regulator of prostate cancer metastasis.
• The Zip7-MAZ-MYBL2 signaling axis plays a key role in promoting PCa bone metastasis.
• Targeting the zinc-dependent Zip7 pathway represents a promising therapeutic strategy for advanced prostate cancer.